Grange J, Dimet J, Vital M, Le Thuaut A, Ducarme G
Service de gynécologie obstétrique, centre hospitalier départemental, Les-Oudairies, 85000 La-Roche-sur-Yon, France.
Unité de recherche clinique, centre hospitalier départemental, Les-Oudairies, 85000 La-Roche-sur-Yon, France.
Gynecol Obstet Fertil Senol. 2017 Oct;45(10):521-527. doi: 10.1016/j.gofs.2017.06.012. Epub 2017 Jul 27.
To compare the efficacy of a double-balloon catheter versus vaginal prostaglandin E2 (dinoprostone) for cervical ripening in obese patients with unfavorable cervix at term.
The study had an open-label, prospective combined with retrospective, observational design. From January 2013 until May 2016, a prospective cohort study of 46 women with pre-pregnancy BMI>30kg/m, live singleton term fetuses (>37 weeks) in vertex presentation and unfavorable cervix (Bishop score<6), who underwent labor induction for conventional indications using a double-balloon catheter. In the same period, 46 obese women who had undergone cervical ripening using vaginal dinoprostone (3mg) were retrospectively included. Women in groups were paired according to Bishop score before the insertion, pre-pregnancy BMI and parity. The primary outcome was a favorable cervix (Bishop score ≥6) 24h after cervical ripening.
After 24h, there was a significantly higher rate of women with favorable cervix (Bishop score ≥6) in the double-balloon group than in dinoprostone group (80.4% vs 47.8%; P=0.001). After adjustment, a double-balloon catheter was significantly associated with an efficient cervical ripening compared to vaginal dinoprostone (aOR 7.81, 95% CI 2.58-23.60). No difference was observed in cesarean section rate (39.1% in each group; P=0.96) and in mean induction time to vaginal delivery (34.5h in the balloon group vs 36.5h in the dinoprostone group; P=0.53). Maternal and neonatal outcomes were similar.
For obese patients at term, cervical ripening using a double-balloon catheter is more efficient on Bishop score after 24h compared to vaginal dinoprostone.
比较双球囊导管与阴道用前列腺素E2(地诺前列酮)对足月宫颈条件不佳的肥胖患者促宫颈成熟的疗效。
本研究采用开放标签、前瞻性结合回顾性的观察性设计。2013年1月至2016年5月,对46例孕前BMI>30kg/m²、单胎足月活胎(>37周)且胎位为头先露、宫颈条件不佳(Bishop评分<6)、因常规指征接受引产并使用双球囊导管的孕妇进行前瞻性队列研究。同期,回顾性纳入46例使用阴道地诺前列酮(3mg)促宫颈成熟的肥胖孕妇。两组孕妇根据放置前的Bishop评分、孕前BMI和产次进行配对。主要结局为促宫颈成熟24小时后宫颈条件良好(Bishop评分≥6)。
24小时后,双球囊组宫颈条件良好(Bishop评分≥6)的女性比例显著高于地诺前列酮组(80.4%对47.8%;P=0.001)。调整后,与阴道地诺前列酮相比,双球囊导管与有效的宫颈成熟显著相关(校正比值比7.81,95%置信区间2.58-23.60)。剖宫产率(每组39.1%;P=0.96)和平均引产至阴道分娩时间(球囊组34.5小时,地诺前列酮组36.5小时;P=0.53)无差异。母婴结局相似。
对于足月肥胖患者,与阴道地诺前列酮相比,使用双球囊导管促宫颈成熟24小时后在Bishop评分上更有效。